CYP2D6 polymorphism in systemic lupus erythematosus patients

European Journal of Clinical Pharmacology

Volumn 55, Issue 1, 1999, Pages 21-25

  Kortunay, S ^a   Bozkurt, A ^a   Bathum, L ^b   Basci, N E ^a   Calguneri M ^a   Brosen K ^c   Kayaalp, S Oǧuz ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Cytochrome P450; Debrisoquine and genetic polymorphism; Systemic lupus erythematosus

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; CLOMIPRAMINE; CYCLOPHOSPHAMIDE; DEBRISOQUINE; DEBRISOQUINE 4 HYDROXYLASE; FAMOTIDINE; HYDROXYCHLOROQUINE; PAROXETINE; PREDNISONE;

ADULT; ALLELE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENZYME ACTIVITY; ENZYME POLYMORPHISM; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC RISK; GENOTYPE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; URINALYSIS;

ADULT; ALLELES; CYTOCHROME P-450 CYP2D6; DEBRISOQUIN; FEMALE; GENOTYPE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC;

EID: 0033063954     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050587     Document Type: Article

References (26)

1. Young RL, Johnson KJ, Richardson BC (1995) Biology of disease: new concepts in the pathogenesis of drug-induced lupus. Lab Invest 73: 746-759
2. Uetrecht JP, Woosley RL (1981) Acetylator phenotype and lupus erythematosus. Clin Pharmacokinet 6: 118-134
3. Cholerton S, Daly AK, Idle JR (1992) The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol Sci 13: 434-438
4. Heim MH, Meyer UA (1992) Evolution of highly polymorphic human cytochrome P450 gene cluster-CYP2D6. Genomics 14: 49-58
5. Daly K, Armstrong M, Monkman SC, Idle ME, Idle JR (1991) Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes. Pharmacogenetics 1: 33-41
6. Daly AK, Cholerton S, Armstrong M, Idle JR (1994) Genotyping for polymorphism in xenobiotic metabolism as a predictor of disease susceptibility. Environ Health Perspect 102: 55-61
7. Baer AN, McAllister CB, Wilkinson GR, Woosley RL, Pincus T (1986) Altered distribution of debrisoquine oxidation phenotypes in patients with systemic lupus erythematosus. Arthritis Rheum 29: 843-849
8. Beyeler C, Armstrong M, Bird HA, Idle JR, Daly AK (1996) Relationship between genotype for the cytochrome P450 CYP2D6 and susceptibility to ankylosing spondylitis and rheumatoid arthritis. Ann Rheum Dis 55: 66-68
9. May DG, Black CM, Olsen NJ, Csuka ME, Tanner SB, Bellino L, Porter JA, Wilkinson GR, Branch RA (1990) Scleroderma is associated with differences in individual routes of drug metabolism: a study with dapsone, debrisoquine and mephenytoin. Clin Pharmacol Ther 48: 286-295
10. Beyeler C, Daly AK, Armstrong M, Astbury C, Bird HA, Idle JR (1994) Phenotype/genotype relationships for the cytochrome P450 CYP2D6 in rheumatoid arthritis: influence of drug therapy and disease activity. J Rheumatol 21: 1034-1039
11. Lahita RG, Bradlow HL, Kunkel HG, Fishman J (1979) Alterations of estrogen metabolism in systemic lupus erythematosus. Arthritis Rheum 22: 1195-1198
12. Lahita RG, Bradlow HL, Fishman J (1981) Increased 16-α-hydroxylation of estradiol in systemic lupus erythematosus. J Clin Endocrinol Metab 53: 174-178
13. Lahita RG, Kunkel HG, Bradlow HL (1983) Increased oxidation of testosterone in systemic lupus erythematosus. Arthritis Rheum 26: 1517-1521
14. Drayer DE, Lorenzo B, Lahita RG, Robbins WC, Reidenberg MM (1982) Microsomal hydroxylation as measured by pentobarbital elimination in patients with idiopathic systemic lupus erythematosus. Clin Pharmacol Ther 32: 195-200
15. Seideman P, Alvan G (1989) Debrisoquine hydroxylation phenotype in systemic lupus erythematosus patients (Letter to the editor). Scand J Rheumatol 18: 63-64
16. Bozkurt A, Başçi NE, Işimer A, Kayaalp SO (1993) Determination of debrisoquine and 4-hydroxydebrisoquine in urine by high-performance liquid chromatography with fluorescence detection after solid-phase extraction. J Pharm Biomed Anal 11: 745-749
17. Evans DAP, Maghoub A, Sloan TP, Idle JR, Smith RL (1980) A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 17: 102-105
18. Heim MH, Meyer UA (1990) Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 336: 529-532
19. Aynacioǧlu Ş, Sachse C, Brockmöller J, Kayaalp SO, Bozkurt A, Başçi NE, Tapanyiǧit EE, Nacak M, Roots I (1997) Allele frequencies of CYP2D6 and CYP2C19 in a Turkish population. Microsomes, drug oxidation and clinical pharmacology; satellite symposium of the 2nd Congress of the EACPT, Berlin, Germany, September 20-21
20. Basci NE, Brosen K, Bozkurt A, Isimer A, Sayal A, Kayaalp SO (1994) S-mephenytoin, sparteine and debrisoquine oxidation: genetic polymorphism in a Turkish population. Br J Clin Pharmacol 38: 463-465
21. Steiner E, Iselius L, Alvan G, Lindsten J, Sjöqvist F (1985) A family of genetic and environmental factors determining polymorphic hydroxylation of debrisoquine. Clin Pharmacol Ther 38: 394-401
22. von Schmiedeberg S, Fritsche E, Rönnau AC, Golka K, Specker C, Schuppe H-C, Döhr O, Sachs B, Bolt HM, Lechmann P, Ruzicka T, Esser C, Abel, J, Gleichmann E (1996) Polymorphisms of drug-metabolizing enzymes in patients with idiopathic systemic autoimmune diseases. Exp Toxicol Pathol 48, [Suppl]: 349-353
23. Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA (1990) Multiple mutations of the human cytochrome IID6 gene (CYP2D6) in poor metabolisers of debrisoquine. J Biol Chem 265: 17209-17214
24. Gough AC, Miles JS, Spurr NK, Moss JE, Gaedigk A, Eichelbaum M, Wolf CR (1990) Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature 347: 773-776
25. Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA (1991) Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet 48: 943-950
26. Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA (1991) Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 10: 545-558